Catalyst Pharmaceuticals, Inc. (FRA:CN2)

Catalyst Pharmaceuticals Statistics

Total Valuation

FRA:CN2 has a market cap or net worth of EUR 2.40 billion. The enterprise value is 1.81 billion.

Market Cap	2.40B
Enterprise Value	1.81B

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	122.91M
Shares Outstanding	n/a
Shares Change (YoY)	+4.21%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	6.16%
Owned by Institutions (%)	85.63%
Float	115.29M

Valuation Ratios

The trailing PE ratio is 12.94 and the forward PE ratio is 9.31.

PE Ratio	12.94
Forward PE	9.31
PS Ratio	4.87
PB Ratio	3.06
P/TBV Ratio	3.56
P/FCF Ratio	12.00
P/OCF Ratio	12.00
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.08, with an EV/FCF ratio of 9.04.

EV / Earnings	9.75
EV / Sales	3.64
EV / EBITDA	7.08
EV / EBIT	8.12
EV / FCF	9.04

Financial Position

The company has a current ratio of 6.62, with a Debt / Equity ratio of 0.00.

Current Ratio	6.62
Quick Ratio	6.19
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 27.52% and return on invested capital (ROIC) is 20.38%.

Return on Equity (ROE)	27.52%
Return on Assets (ROA)	17.74%
Return on Invested Capital (ROIC)	20.38%
Return on Capital Employed (ROCE)	28.04%
Revenue Per Employee	2.72M
Profits Per Employee	1.02M
Employee Count	181
Asset Turnover	0.63
Inventory Turnover	4.06

Taxes

In the past 12 months, FRA:CN2 has paid 58.15 million in taxes.

Income Tax	58.15M
Effective Tax Rate	23.87%

Stock Price Statistics

The stock price has decreased by -6.36% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-6.36%
50-Day Moving Average	18.28
200-Day Moving Average	19.15
Relative Strength Index (RSI)	58.17
Average Volume (20 Days)	327

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.73

Income Statement

In the last 12 months, FRA:CN2 had revenue of EUR 492.80 million and earned 185.43 million in profits. Earnings per share was 1.46.

Revenue	492.80M
Gross Profit	409.68M
Operating Income	220.55M
Pretax Income	243.58M
Net Income	185.43M
EBITDA	252.77M
EBIT	220.55M
Earnings Per Share (EPS)	1.46

Balance Sheet

The company has 587.99 million in cash and 2.46 million in debt, giving a net cash position of 585.53 million.

Cash & Cash Equivalents	587.99M
Total Debt	2.46M
Net Cash	585.53M
Net Cash Per Share	n/a
Equity (Book Value)	784.32M
Book Value Per Share	6.36
Working Capital	616.82M

Cash Flow

In the last 12 months, operating cash flow was 200.00 million and capital expenditures -97,162, giving a free cash flow of 199.90 million.

Operating Cash Flow	200.00M
Capital Expenditures	-97,162
Free Cash Flow	199.90M
FCF Per Share	n/a

Margins

Gross margin is 83.13%, with operating and profit margins of 44.76% and 37.63%.

Gross Margin	83.13%
Operating Margin	44.76%
Pretax Margin	49.43%
Profit Margin	37.63%
EBITDA Margin	51.29%
EBIT Margin	44.76%
FCF Margin	40.56%

Dividends & Yields

FRA:CN2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.21%
Shareholder Yield	-4.21%
Earnings Yield	7.73%
FCF Yield	8.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:CN2 has an Altman Z-Score of 14.94 and a Piotroski F-Score of 5.

Altman Z-Score	14.94
Piotroski F-Score	5